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Abstract  
Thiamine prevents high glucose-induced damage in microvasculature, and progression of 
retinopathy/nephropathy in diabetic animals. Impaired thiamine availability causes renal damage in 
diabetic patients. Two SNPs in SLC19A3 locus encoding for thiamine transporter-2 (THTR2) are associated 
with absent/minimal diabetic retinopathy/nephropathy despite long-term type-1 diabetes. We investigated 
the involvement of THTR1, THTR2, and their transcription factor Sp1, in high glucose-induced damage and 
altered thiamine availability in cells of the inner blood-retinal barrier. 
Human endothelial cells, pericytes, and Müller cells were exposed to hyperglycaemic-like conditions and/or 
thiamine deficiency/oversupplementation in single/co-cultures. Expression and localization of THTR1/ 
THTR2/Sp1, intracellular thiamine, transketolase activity and permeability to thiamine were studied, 
together with the effects of thiamine depletion on cell function. THTR2/Sp1 expressions were modulated by 
hyperglycaemic conditions. Transketolase activity, intracellular thiamine and permeability decreased in 
cells cultured in thiamine-deficiency, and in pericytes in hyperglycaemic conditions. Thiamine depletion 
reduced cell viability and proliferation, while thiamine oversupplementation compensated for THTR2 
reduction by restoring thiamine uptake and transketolase activity. High glucose and reduced thiamine 
determine impairment in thiamine transport inside cells and through the inner blood-retinal barrier. THTR2 
modulation suggests its major role in thiamine transport in retinal cells and involvement in high glucose-
induced damage and impaired thiamine availability.  
 
 
Keywords: diabetic retinopathy, inner blood-retinal barrier, thiamine, thiamine transporter, transketolase 
Abbreviations: EC, endothelial cells; ETDRS, Early Treatment Diabetic Retinopathy Study; DR, diabetic retinopathy; 
HIF-1α, Hypoxia-Inducible transcription Factor-1 alpha; HMEC, human microvascular endothelial cells; HG, high D-
glucose concentrations; HRP, human retinal pericytes; HT, high thiamine concentrations; intHG, intermittent high D-
glucose concentrations; MIO-M1, human Müller cell line Moorfields/Institute of Ophthalmology-Müller 1; NG, 
physiological D-glucose concentration; ROS, reactive oxygen species; Sp1, transcription factor specificity protein-1; TD, 
thiamine deficiency/deficient; THTR-1, thiamine transporter-1; THTR-2, thiamine transporter-2; TK, transketolase; 
TRMA, thiamine-responsive megaloblastic anaemia; VEGF, Vascular Endothelial Growth Factor. 
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Key messages 
 Hyperglycemia concurs with reduced thiamine availability to determine impairment in thiamine 
transport inside retinal cells and through the inner blood-retinal barrier 
 
 Thiamine transporter-2 (THTR2) is modulated in cell models mimicking the diabetic retinal 
microenvironment 
 
 THTR2 modulation suggests its primary role in thiamine transport inside retinal cells and its 
involvement in high glucose-induced damage and impaired thiamine availability 
 
 Retinal pericytes are the most sensitive to the impaired environmental conditions in terms of 
THTR2 modulation and altered thiamine uptake, confirming to be the first target of metabolic 
damage in the retinal microenvironment 
 
 Thiamine administration to diabetic subjects may help to prevent or counteract microvascular 
complications 
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Introduction 
Diabetic microangiopathy is a major cause of blindness, renal failure and nerve damage. Duration of 
diabetes, poor glycaemic control and high blood pressure are the most important risk factors for its 
development. Although intervention studies have clearly linked the severity of microvascular complications 
with the duration and severity of hyperglycaemia [1-3], a sub-analysis of the DCCT showed that 10% of 
patients developed a 3-step ETDRS progression of DR despite being in the lowest HbA1c quintile (<6.87%), 
whereas 43% of those in the worst quintile (HbA1c >9.49%) did not develop any [4]. This and other findings 
showing familial clustering of microvascular complications [5,6] suggest that other factors may play a major 
role in the pathogenesis of diabetic microangiopathy.  
High glucose induces vascular damage through different mechanisms, among which increased activation of 
the polyol, diacylglycerol-protein kinase C and hexosamine pathways, and overproduction of advanced 
glycation end-products seem to play a major role. ROS overproduction by mitochondria, as a result of 
increased flux through the Krebs’ cycle, was reported as the unifying mechanism of these biochemical 
pathways [7]. 
Thiamine is an essential coenzyme for key-enzymes of intracellular glucose metabolism, in particular 
transketolase, which shifts excess potentially damaging metabolites from glycolysis into the pentose-
phosphate cycle [8,9]. Thiamine, and its lipophilic derivative benfotiamine, normalize the four branches of 
the above-described unifying mechanism of glucose damage [7], by reducing ROS production in cell and 
animal studies [10, 11]. In vivo, thiamine/benfotiamine administration reduced progression of DR and 
nephropathy in diabetic animals [10, 12]. 
Thus, reduced thiamine availability may facilitate metabolic damage. Renal loss of thiamine due to disposal 
via proximal tubules, resulting in reduced thiamine/TK activity, was described in diabetic patients [13]. 
Hence, diabetes might be described as a thiamine-deficient state, relatively to the increased coenzyme 
requirements deriving from amplified glucose metabolism, especially in non-insulin dependent tissues 
prone to complications [9].  
Thiamine is present in free form and very low concentrations in the intestinal lumen; absorption takes 
place mainly in the proximal part of the small intestine, through two mechanisms [14]. At high, 
pharmacological concentrations, non-saturable passive diffusion may occur [15]. At low concentrations, it is 
carried into the cells by high-affinity active transport, involving phosphorylation of the vitamin, and 
mediated by two transporters, THTR1 and THTR2, encoded respectively by the SLC19A2 and SLC19A3 genes 
[16]. Sp1 is responsible for the basal expression of THTR1 and THTR2 [17,18]. THTR1 and THTR2 are both 
widely distributed but their expression may vary in different tissues [19]. 
Susceptibility to develop DR and/or nephropathy may correlate with impaired ability to achieve 
intracellular thiamine levels sufficiently high to cope with increased glucose inflow. This might be 
particularly relevant in insulin independent tissues, such as retinal capillary endothelium, pericytes and 
neuroretina, because they cannot regulate glucose uptake and are more exposed to hyperglycaemic 
damage.  
Some evidence for modulation of thiamine transporters in high glucose has been reported. Glucose-
induced down-regulation of THTR1 and 2, and Sp1, linked to thiamine insufficiency, was shown in human 
kidney proximal tubular epithelium [20]. On the other hand, adaptive regulation of thiamine uptake 
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consequent to extracellular substrate levels was described, with overexpression of THTR2 and Sp1, but not 
THTR1, in human intestinal epithelial cells maintained in a low thiamine medium [21]. 
Finally, the minor alleles of two SNPs in the SLC19A3 locus are strongly associated with absent/minimal DR 
and diabetic nephropathy despite type-1 diabetes of more than 20 years duration, suggesting a role for 
genetic variations of THTR2 in the pathogenesis of severe DR and end-stage renal disease, eventually 
explaining why some diabetic patients are less prone than others to develop microvascular complications. 
Such association reached genome-wide significance in the combined analysis of the FinnDIANE and WESDR 
cohorts, the largest series of fully genotyped type-1 diabetic patients available today [22]. 
The aim of this work was to investigate the involvement of the two thiamine transporters THTR1 and THTR2 
and their transcription factor Sp1 in high glucose-induced damage and altered thiamine availability in cell 
models belonging to the inner blood-retinal barrier, cultured in conditions mimicking the diabetic 
retinopathy microenvironment. 
 
Materials and Methods 
Cell cultures 
A HRP line had been stabilized and characterized in our laboratory [23]. HMEC were from ATCC (Cat# CRL-
3243, RRID:CVCL_0307), and MIO-M1 cells were obtained from the UCL Institute of Ophthalmology, 
London, UK (RRID:CVCL_0433) [24]. HRP and MIO-M1 cells were cultured in DMEM + 10%FCS; HMEC in 
EBM-2 growth medium (Lonza, Basel, Switzerland) for expansion and switched to DMEM + 10%FCS for 
experiments. All cell types were mycoplasma-free as detected by RT-PCR. 
Cells were cultured for 8 days in NG (5.6 mmol/l), HG (28 mmol/l) or intHGt (48hr HG/48hr NG twice) D-
glucose concentrations, to mimic the diabetic microenvironment. To investigate substrate influence on the 
expression of thiamine transporters, thiamine was added at a pharmacological dose of 50 µmol/l (HT), 
while custom-made thiamine-deficient media (TD) (Thermo Fisher Scientific, Waltham, MA, USA) was used 
to test the effects of low thiamine environment. 
In order to create an in vitro model of the inner blood-retinal barrier and study the interactions among the 
different cell types involved, we also established tri-co-cultures, by growing HMEC on the inner membrane 
surface, and HRP on the outer surface, of transwell inserts, while Műller cells were plated on the bottom of 
the well, as previously described [25]. Co-cultures were maintained for 8 days in the above-described 
experimental conditions. At the end of the incubation period, inserts were shifted to new wells; trypsin-
EDTA was added inside the insert to detach ECs, and inside the well at a volume sufficient to wet the 
bottom of the insert, to detach HRPs. MIO-M1 were collected by trypsinization from the bottom of the 
original wells. 
Modulation of the expression of thiamine transporters THTR1/2 and Sp1 
Quantitative Real Time PCR (qRT-PCR) 
THTR1/2 and Sp1 mRNA expression was evaluated by qRT-PCR. Total RNA was extracted by HighPure RNA 
Isolation kit (Sigma-Aldrich, St. Louis, MO, USA) and 200 ng RNA were reverse-transcribed using High 
Capacity cDNA Reverse Transcription Kits (Thermo Fisher Scientific). qRT-PCR was performed by 48-well 
StepOne Real Time System (Applied Biosystems, Foster City, CA, USA) using Power SYBR™ Green PCR 
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Master Mix (Thermo Fisher Scientific). Relative gene expression was determined using the 2-ΔΔCT method 
and normalized against β-actin. Primers used were: THTR1 forward: 5’-AGCCAGACCGTCTCCTTGTA-3’; 
reverse: 5’-TAGAGAGGGCCCACCACAC-3’ [26]; THTR2 forward: 5’-CTGGCTCTGGTGGTCTTCTC-3’, reverse: 5’-
AGGCATAGCGTTCCACATTC-3’; Sp1 forward: 5’-TGCAGCAGAATTGAGTCACC-3’, reverse: 5’-
CACAACATACTGCCCACCAG-3’ [20]. 
Western blot analysis 
THTR1/2 and Sp1 protein expression was evaluated by Western blot analysis. To extract total proteins, cells 
were lysed using M-PER Mammalian Protein extraction reagent (Thermo Fisher Scientific) added with 10 
µl/ml protease inhibitor cocktail kit (Thermo Fisher Scientific). Extracts were kept ice-cold and cleared by 
centrifugation at 20,000 g for 15 min at 4°C. The supernatant was aliquoted and stored at −80°C. Protein 
content was measured through Bradford reaction. 
30 µg proteins were loaded on pre-cast gels (4–20% Mini-PROTEAN® TGX™ Precast Gel, Bio-Rad, Hercules, 
CA, USA), separated by electrophoresis and transferred to nitrocellulose membranes. Immunoblotting was 
performed by incubating the membranes with rabbit polyclonal antibody anti-SLC19A2 (Abcam Cat# 
ab123246, RRID:AB_10972351) 1:1000, anti-SLC19A3 (Abcam Cat# ab103950, RRID:AB_10711742) 1:500, 
and anti-SP1 (Thermo Fisher Scientific Cat# PA5-27243, RRID:AB_2544719) 1:2000. Immunoreactive bands 
were visualized using the enhanced chemiluminescence (ECL) Western blotting protocol (Merck-Millipore, 
Darmstadt, Germany). The relative signal strength was quantified by densitometric analysis (1D Image 
Analysis System, Kodak), and values normalized against β-actin.  
Localization of thiamine transporters THTR1/2 and Sp1 
Cells cultured as described above were transferred to chamber slides for the last 24 hrs. They were then 
fixed in ice-cold methanol for 5 min at -20°C, dried at RT for 15 min and re-hydrated in PBS for 15 min. Non-
specific binding sites were blocked in PBS plus 0.2% BSA (blocking solution) for 1h at RT. Cells were 
incubated overnight at 4°C with 1 µg/ml rabbit polyclonal anti-SLC19A2 (Sigma-Aldrich Cat# HPA006119, 
RRID:AB_1079996), 2 µg/ml rabbit polyclonal anti-SLC19A3 (Sigma-Aldrich Cat# HPA038898, 
RRID:AB_10673481), or 1:250 rabbit polyclonal anti-SP1 (Thermo Fisher Scientific Cat# PA5-27243, 
RRID:AB_2544719), as appropriate. Following three washings with blocking solution, 1:1000 FITC-
conjugated goat anti-rabbit IgG (Abcam Cat# ab6717, RRID:AB_955238) was added for 1h at RT. DAPI was 
used to blue-stain the cell nuclei. Images were taken under a Leica DM 2000 microscope (Leica, Wetzlar, 
Germany), equipped with a Leica DFC 320 camera and Leica QWin Plus 2003 digital processing and analysis 
software. 
Intracellular thiamine uptake 
Intracellular thiamine uptake was measured in cell lysates through the DRG® Vitamin B1 (Thiamine) (BIO-
5136) kit (DRG International, Springfield, NJ, USA). 150 µl of 1:5 diluted lysate and 150 µl medium from the 
kit were added to 96-well plates coated with Lactobacillus fermentum. The presence of thiamine in samples 
gives a thiamine-dependent growth response until the vitamin is consumed. After incubation at 37°C for 48 
h, the growth of L. fermentum was measured turbidimetrically at 630 nm. Thiamine concentration is 
directly proportional to the turbidity. Values were normalized by protein content. 
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Transketolase activity 
Transketolase activity was evaluated using a modification of the enzymatic kinetic method of Chamberlain 
et al. [27], as previously described [11]. The enzyme reaction was started by the addition of 15µl cell lysate 
to 85µl reaction mixture (15 mmol/l ribose-5-phosphate, 250 µmol/l NADH, 0.1 mol/l Tris-HCl pH7.8, 200 
U/ml glycerol-3-phosphate dehydrogenase/triose phosphate isomerase) and the 340 nm absorbance 
measured at 10 min intervals for 90’. TK activity was deduced from the difference in the absorbance at t=0 
and t=30’ for HMEC/MIO-M1 cells, and t=0 and t=60’ as regards HRP. Values were normalized by protein 
content. 
Permeability to thiamine of HMEC/HRP bilayers  
Permeability to thiamine of HMEC/HRP bilayers was measured in transwell inserts, by culturing cells on 
either side of the membrane, as described above. Once confluence was reached, medium was changed to 
thiamine-deficient medium. 50 µmol/l thiamine were added to the upper chamber and thiamine content 
measured in the lower chamber after 1 hr incubation, as described above. 
Effects of thiamine deficiency on cell function 
To evaluate the role of thiamine depletion on cell function, retinal cells were cultured for 8 days in 
physiological glucose/thiamine concentrations (NG ctrl), physiological glucose/thiamine deficiency (NG TD), 
stable high glucose/thiamine deficiency (HG TD) and intermittent high glucose/thiamine deficiency (intHG 
TD), as described above. 
Cell number was assessed by cell counting in Bürker chambers after Trypan blue staining, by two 
independent operators. Proliferation was evaluated by bromo-deoxy-uridine (BrdU) incorporation into the 
DNA (Cell Proliferation Assay, BrdU, Roche Applied Science, Mannheim, Germany), according to the 
manufacturer’s instructions. Apoptosis, in terms of DNA fragmentation, was assessed by ELISA, according to 
instructions (Cell Death Detection ELISAplus, Roche). As regards migration, at the end of the incubation 
period retinal cells were seeded inside 8 µm-pore polycarbonate membrane transwells in DMEM without 
FCS. DMEM + 10% FCS was used as a chemoattractant in the lower chamber. After 24 hrs their migration 
rate was measured using the colorimetric QCM Chemotaxis Cell Migration Assay (Merck-Millipore, 
Darmstadt, Germany).  Cell proliferation, apoptosis and migration were normalized to cell number. 
 
Statistics 
Statistical comparison was performed by one-way ANOVA with Bonferroni post-hoc correction. Results 
were expressed as mean ± SD of 5 independent experiments, as previously established through a power 
analysis, and normalized against cells cultured in physiological conditions (NG). 
 
Results 
Expression and localization of thiamine transporters and Sp1 in retinal cells in physiological conditions 
ECs, pericytes and Müller cells express all the two thiamine transporters and their transcription factor Sp1 
in physiological conditions (Fig. 1). THTR1 and Sp1 are expressed similarly in all cell types, while THTR2 
expression is lower in ECs and higher in pericytes (Fig. 1 a-b). Sp1 concentration is higher in all cell types, in 
comparison with thiamine transporters. 
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As regards their localization inside the cells, THTR1 presents a cytoplasmic distribution in all cell types (Fig. 
1 c-f-i), but while in HMEC it locates closer to the cell membrane (Fig. 1 c), in HRP and Müller cells it seems 
to remain mostly close to the Golgi apparatus (Fig. 1 f-i). THTR2 localizes to cytosol in HMEC (Fig. 1 d), while 
in pericytes and Müller cells it shows a nuclear bodies distribution (Fig. 1 g-j). Sp1 has a cytoplasmic 
distribution in ECs and pericytes (Fig. 1 e-h), while in Müller cells it locates along the cell membrane (Fig. 1 
k). 
Expression and localization of thiamine transporters and Sp1 in retinal cells under different experimental 
conditions 
Cells were cultured in physiological, high or intermittent low/high glucose concentrations, to mimic the 
diabetic microenvironment. In addition, substrate influence on the expression of thiamine transporters was 
investigated adding to each glucose condition thiamine at pharmacological doses, or using thiamine-
deficient media. mRNA and protein expression of each transporters and Sp1 was evaluated in all 
experimental conditions. 
THTR1 mRNA and protein expressions were unchanged in all cases and in all cell types (Fig. 2), while THTR2 
(Fig. 3) and Sp1 (Fig. 4) showed different behaviours in the three cell types. 
THTR2 mRNA expression decreased in HRP cultured in HG in all thiamine conditions (-17% vs NG ctrl in all 
cases, p<0.05), in intHG in standard thiamine (-32% vs NG ctrl, p<0.05) and TD conditions (-16% vs NG ctrl, 
p<0.05), and in NG TD (-13%, p<0.05) (Fig. 3 c). On the contrary, THTR2 mRNA expression increased in 
HMEC in HG and intHG in standard thiamine concentrations (+20% and +30% vs NG ctrl respectively, 
p<0.05) and TD (+30% and +27%, respectively, p<0.05) (Fig. 3 a). Increased THTR2 expression was also 
found in Müller cells in intHG (+22% vs NG ctrl, p<0.05), while intHG TD conditions decreased THTR2 
expression (-26% vs NG ctrl, p<0.05) (Fig. 3 e). 
THTR2 protein expression showed a 40% increase in HMEC cultured in HG and intHG TD conditions (p<0.05 
vs NG ctrl) (Fig. 3 b) and a 20% decrease in HRP in HG and intHG with standard thiamine concentrations 
(p<0.05 vs NG ctrl) (Fig. 3 d). In Müller cells, THTR2 protein expression increased by an average 30% in HG 
TD, HG HT and in intHG in all thiamine conditions (p<0.05 vs NG ctrl) (Fig. 3 f). 
Sp1 mRNA expression was unchanged in HMEC and MIO-M1 cells in all experimental conditions (Fig. 4 a,e), 
while it decreased of a 20-25% in HRP cultured in HG, HG TD, intHG, intHG TD conditions (p<0.05 vs NG ctrl) 
(Fig. 4 c). Sp1 protein expression increased in HMEC in HG, HG HT and intHG (p<0.05 vs NG ctrl) (Fig. 4 b), 
decreased in HRP in HG, HG HT and int HG in all thiamine conditions (p<0.05 vs NG ctrl) (Fig. 4 d), and was 
unchanged in Müller cells (Fig. 4 f). 
As regards the intracellular localization of thiamine transporters and Sp1 examined by immunofluorescence 
staining, no modifications were found among the different experimental conditions (data not shown). 
Expression of thiamine transporters and Sp1 in co-cultured retinal cells in different experimental 
conditions 
HMEC, HRP and MIO-M1 cells were cultivated all together in a tri-co-culture system, to mimic the inner 
blood-retinal barrier microenvironment. We meant to understand if co-culture might influence thiamine 
transporter expression differently from single cultures. As our previous data in single cultures seemed to 
rule out a primary involvement of different thiamine concentrations on transporters and Sp1 expression, 
cells were cultured in NG, HG and intHG only. 
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THTR1 mRNA and protein expression were again unchanged in all cases and in all cell types (Fig. 5 a-b). 
THTR2 mRNA expression showed a superimposable behaviour in co-cultured HRP and MIO-M1 cells with 
respect to single cultures. On the contrary, THTR2 mRNA expression in HMEC, which was increased in single 
cultures, appeared to decrease when cells were cultured in HG in the tri-co-culture system (Fig. 5 c). As 
regards THTR2 protein expression, it decreased in HRP in HG and intHG (p<0.05 vs NG), confirming single 
culture data, while it was unchanged in HMEC and even decreased in Müller cells in HG and intHG 
conditions (p<0.05 vs NG) (Fig. 5 d).  
Sp1 mRNA expression was unchanged in all cell types (Fig. 5 e), while its protein expression decreased in 
HRP in HG and intHG conditions (p<0.05 vs NG) (Fig. 5 f). 
Intracellular thiamine uptake and transketolase (TK) activity in retinal cells 
As indirect measures of thiamine transporter function, we investigated intracellular thiamine uptake and TK 
activity in retinal cells under all the different experimental conditions. 
As expected, we found a dramatic decrease in thiamine uptake and a concomitant reduction in TK activity 
when HMEC and HRP were cultured in TD conditions (p<0.001) (Fig. 6 a-d). Moreover, HRP showed a 
decrease in both parameters, when cultured in intHG conditions in comparison with physiological 
conditions (-15% and -13% respectively, p<0.05), while HT addition to intHG restored them (Fig. 6 b-c). 
Müller cells showed a different behaviour: thiamine uptake was decreased in NG TD and intHG TD, and 
unchanged when cells were grown in HG HT (Fig. 6 e). Moreover, TK activity was even increased in HG TD 
and intHG TD in comparison with physiological conditions (p<0.05) (Fig. 6 f). 
Permeability to thiamine of HMEC/HRP co-cultures 
We assessed thiamine passage through HMEC/HRP confluent bilayers that had been previously exposed to 
all experimental conditions. 
As shown in Fig. 7, thiamine release through the bilayer was decreased when HMEC/HRP had been 
previously exposed to TD, in all glucose conditions (p<0.05 vs NG ctrl), and also when cells had been pre-
treated with intHG (p<0.05 vs NG ctrl). 
Effects of thiamine deficiency on cell function 
To evaluate the effects of thiamine depletion on cell function, we cultured HMEC, HRP and MIO-M1 cells in 
the three different glucose conditions in TD medium. As shown in Fig. 8a, cell number after 8-day 
incubation was significantly decreased in all cell types in TD media in comparison with physiological control 
(p<0.05 vs NG ctrl). In HMEC, both HG and intHG conditions worsened this effect of a further 33% (p<0.05 
vs NG TD), while HRP number was decreased of a further 25% by intHG TD only (p<0.05 vs NG TD and HG 
TD). Superimposable results were found in HMEC and HRP as regards cell proliferation (Fig. 8b), while MIO-
M1 proliferation was not affected by TD. Thiamine depletion had no effect on apoptosis (Fig. 8c) or 
migration (Fig. 8d) in all cell types. Nevertheless, apoptosis was increased in HRP cultured in intHG TD 
conditions (+96% vs NG ctrl, p<0.05 vs NG ctrl, NG TD, HG TD). 
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Discussion 
In this work, we show that conditions mimicking a diabetic retinal microenvironment may influence the 
expression of thiamine transporters; in particular, THTR2 seems to be mainly affected by high glucose-
induced damage in retinal cells. In addition, thiamine supplementation may help to by-pass THTR2 
reduction by restoring, in pericytes, impaired thiamine uptake and transketolase activity due to damage 
induced by hyperglycaemic-like conditions.  
We had previously demonstrated that human retinal pericytes are more sensitive to intermittent than to 
stable high glucose concentrations, in terms of survival and apoptosis [28]. This is not surprising, as diabetic 
patients undergo glycaemic fluctuations during the day. Similar results were also found with endothelial 
cells [29]. As regards Müller cells, however, we have no evidence yet of major sensitivity to one or another 
high glucose model. Therefore, we decided to culture all cell types in both stable and intermittent high 
glucose concentrations, in order to obtain comparable data. 
A major role for thiamine in the prevention of diabetic complications has been widely described [9,10]. In 
particular, thiamine is able to counteract high glucose-induced damage in microvascular cells, by 
normalizing the four metabolic pathways enhanced by excess glucose [7], and thus reducing ROS 
production [10,11]. Moreover, its administration in diabetic animals reduces the progression of DR and 
nephropathy [10,12], and renal loss of this vitamin, with consequent reduced TK activity, was shown in 
diabetic patients [13].  
Since thiamine is a water-soluble vitamin, non-saturable passive diffusion through the cell membrane may 
occur at pharmacological concentrations only [15]. Usually, at low, physiological concentrations, its 
internalization inside the cells involves phosphorylation, and is mediated by two specific transporters, 
THTR1 and THTR2 [16], the expression of which is in turn mediated by the transcription factor Sp1 [17,18]. 
THTR1 deficiency is known to cause TRMA, also called Rogers syndrome, characterized by megaloblastic 
anaemia, diabetes and sensorineural deafness [30,31]. On the other hand, defects in SLC19A3 gene 
encoding for THTR2 and resulting in truncated proteins are responsible for biotin responsive basal ganglial 
disease [32] and thiamine responsive encephalopathy [33]. More recently, it has been demonstrated that 
two SNPs located in intronic regions of SLC19A3 are strongly associated with absent or minimal DR and DN 
despite long duration type-1 diabetes, but their functional meaning is still unknown [22].  
The distribution of the two transporters and their kinetics vary in different tissues [19]. While THTR1 and 
the transcription factor Sp1 seem to be more ubiquitous, THTR2 has been described mainly in the intestine, 
liver, kidney and placenta but is absent from marrow stem cells, pancreatic beta cells and cochlear hairy 
cells of the inner ear [20, 34-35]. Predisposition to the development of diabetic microvascular 
complications may be related to the relative capacity of insulin-independent tissues to uptake enough 
thiamine to counteract excess glucose exposition. Our results demonstrate the presence of both 
transporters and Sp1 in all cells of the inner blood-retinal barrier, i.e. endothelial cells, pericytes and Müller 
cells. THTR1 presents a cytoplasmic distribution in all cell types, consistently with the approved distribution 
by The Human Protein Atlas (https://www.proteinatlas.org/). On the contrary, THTR2 shows different 
locations: to the cytosol in ECs, while showing a nuclear bodies distribution in pericytes and Müller cells. 
These data are partially consistent with the approved distribution of THTR2 in the Human Protein Atlas 
which reports THTR2 to be mainly localized to the nucleoplasm and in addition to the cytosol. Also the 
localization of Sp1 to the cytosol in our cell types differs from the nucleoplasm distribution reported by the 
Atlas. However, to our knowledge, this is the first time that thiamine transporter localization has been 
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addressed in EC, pericytes and Müller cells, which are not comprised among those examined by the Atlas. 
Consequently, we can hypothesize that protein localization may present differences in such a peculiar 
microenvironment as the inner blood retinal barrier. The internal cell localization of the transporters and 
Sp1 was confirmed in all experimental conditions, regardless of glucose and/or thiamine concentrations. 
Previous findings show a certain degree of cell specificity as regards modulation of transporters and Sp1 in 
response to environmental changes in the concentration/availability of either glucose or thiamine. THTR1 
expression was not affected by either thiamine supplementation or deficiency in epithelial Caco-2 cells [21], 
while the same work reported increased THTR1 expression in ARPE-19 cells, inversely correlated to 
extracellular thiamine concentrations [26]. Decreased THTR1 expression was demonstrated in human 
primary proximal tubule epithelial cells cultured in high glucose concentrations [20]. Our data show no 
changes in THTR1 mRNA and protein expression in our cells in different glucose and/or thiamine 
concentrations. On the contrary, THTR2 expression shows different, cell-specific behaviours: overall 
increase in ECs and Müller cells and decrease in pericytes, in the presence of high/intermittent glucose 
conditions, independent from extracellular thiamine concentration. This apparent paradox can be again 
interpreted as cell specificity, and as such supported by the literature: THTR2 expression is downregulated 
by high glucose conditions in human primary proximal tubule epithelial cells [20] and HUVECs [37], and 
upregulated by thiamine deficiency in Caco-2 [21] and ARPE-19 cells [26]. Moreover, THTR2 expression is 
reported to be differently affected by other pathological conditions: down-regulated in the intestine, heart, 
liver and brain of Sprague-Dawley rats with chronic kidney disease [38] and up-regulated in breast cancer 
[39], while no differences were recently found in erythrocytes and plasma levels of THTR2 in diabetic vs 
non-diabetic subjects [37]. THTR1 and THTR2 expression are modulated by their transcription factor Sp1: in 
our experimental setting, Sp1 expression is consistent with THTR2 expression in both ECs and pericytes, and 
substantially unchanged in Müller cells.  
To investigate their possible mutual influence, we subsequently studied THTR1, THTR2 and Sp1 expression 
in ECs, pericytes and Müller cells cultured all together in a tri-co-culture system, aimed at partially 
mimicking the complex milieu of the inner blood-retinal barrier. In these conditions, pericytes showed the 
same behaviour as in single cultures: a decrease in THTR2 and Sp1 expression, and no variation in THTR1. 
On the contrary, ECs and Müller cells were influenced by the surrounding cell types, with both THTR2 
mRNA and protein expression decreased in ECs co-cultured in HG, showing an opposite behaviour from 
single cultures. In Müller cells, while THTR2 mRNA expression increased consistently with single cultures, its 
protein concentration decreased in HG and intHG conditions. These findings confirm the need of using cell 
models as similar as possible to the retinal microenvironment. 
As expected, intracellular thiamine concentration, and consequently TK activity, were dramatically 
decreased in ECs and pericytes exposed to thiamine-deficient media. In these cells, thiamine depletion 
strongly affects also viability and proliferation, while it has no effect on apoptosis and migration. However, 
these results were obtained in cells still attached to the wells, therefore we cannot exclude that a part of 
the cells could have undergone apoptosis and detached during incubation. In pericytes, moreover, thiamine 
uptake and TK activity were also decreased in intermittent high glucose, in accordance with the decreased 
THTR2 expression we found in these cells, while thiamine supplementation was able to restore 
physiological values when added to intHG. During DR, the hypoxic retinal environment induces the 
activation of HIF-1α, which in turn causes VEGF accumulation. VEGF is the main actor of neo-angiogenesis 
that is facilitated by loss of pericyte control on endothelial proliferation. Recent evidence suggests that, 
consistently with hypoxia, thiamine deficiency may determine increased HIF-1α and, consequently, VEGF 
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expression, through excess accumulation of pyruvate and lactate [40], thus concurring to the worsening of 
DR.  
On the contrary, Müller cells cultured in high glucose showed no decrease in intracellular thiamine 
concentration, even in thiamine-deficient conditions. This was associated with increased TK activity and 
THTR2 expression in Müller cells kept in the same conditions, and suggests an adaptive regulation of 
thiamine uptake mediated by increased expression of the transporter, consistently with previous results on 
ARPE-19 cells, in which thiamine uptake was found to be inversely correlated with extracellular thiamine 
availability [26]. Moreover, Müller cells seem to be less affected by thiamine deficiency also in terms of 
proliferation, suggesting an overall reduced sensitivity of Müller cells to thiamine depletion, in comparison 
with microvascular cells. 
Permeability to thiamine of ECs/pericytes co-cultures, i.e. release of excess thiamine at the opposite side of 
the bilayer, was reduced in cells that had been previously grown in thiamine-deficient medium, probably 
due to an attempt of the cells, after 8-day starvation, to restore physiological intracellular concentrations of 
the vitamin. Concurrently, permeability to thiamine was also decreased in co-cultures exposed to 
intermittent high glucose conditions, and prevented by thiamine over-supplementation. This may be 
explained by the major requirement of thiamine inside the cell to counteract intermittent hyperglycaemia-
induced damage [9]. 
We are aware that each model used to mimic diabetic retinal microenvironment has its own weaknesses. 
We have re-created a cell model of the inner blood-retinal barrier, as close as possible to retinal 
microvessels in diabetes, using human cells only. Moreover, pericytes and Müller cells are of retinal origin, 
even though they are cell lines and not primary cells. Our pericyte line was indeed validated for glucose 
metabolism studies [23], and it showed superimposable behaviour towards glucose-induced damage to the 
primary cells from which it was derived [28]. The same applies to the Müller cell line [24]. As regards HMEC, 
they are a cell line of dermal origin, but widely used as a model of microvascular ECs in works regarding 
several districts of the body, including diabetic retinopathy [41]. In the future, development of a reliable 
human retinal EC line will help avoiding this potential pitfall. 
In conclusion, high glucose conditions concur with reduced substrate availability to determine impairment 
in thiamine transport inside retinal cells and through the inner blood retinal barrier. The main actor of this 
damage seems to be THTR2, whose modulation in cell models mimicking the diabetic retinal 
microenvironment suggests its major role in thiamine transport in retinal cells and its involvement in high 
glucose-induced damage and impaired thiamine availability. Of the three retinal cell types we examined, 
pericytes seem to be the most sensitive to the impaired environmental conditions in terms of THTR2 
modulation and altered thiamine uptake, confirming once more to be the first target of metabolic damage 
in the retinal microenvironment. Thiamine supplementation to diabetic patients may thus be foreseen as a 
strategy to prevent or counteract microvascular complications. 
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Fig. 1 Expression of thiamine transporters and Sp1 in retinal cells in physiological conditions. a-b) 
Comparison of mRNA (a) and protein expression (b) in the different cell types. c-k) Localization of thiamine 
transporters and Sp1 inside retinal cells in physiological conditions. Immunofluorescence with Ab anti-
THTR1 (c-f-i), anti-THTR2 (d-g-j) and anti-Sp1 (e-h-k) in HMEC (c-d-e), HRP (f-g-h) and MIO-M1 cells (i-j-k) 
(green). Nuclei are counterstained with DAPI (blue). Magnification 400x 
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Fig. 2 THTR1 expression in retinal cells under different experimental conditions. a) THTR1 mRNA and b) 
protein expression in HMEC; c) THTR1 mRNA and d) protein expression in HRP; e) THTR1 mRNA and f) 
protein expression in MIO-M1 cells. Mean of 5 experiments ± SD, plus representative images of one 
relevant WB experiment. White bars: physiological thiamine concentrations (ctrl); light grey bars: thiamine-
deficient medium (TD); dark grey bars: high thiamine concentrations (HT) 
  
18 
 
 
Fig. 3 THTR2 expression in retinal cells under different experimental conditions. a) THTR2 mRNA and b) 
protein expression in HMEC; c) THTR2 mRNA and d) protein expression in HRP; e) THTR2 mRNA and f) 
protein expression in MIO-M1 cells. Mean of 5 experiments ± SD, plus representative images of one 
relevant WB experiment. White bars: physiological thiamine concentrations (ctrl); light grey bars: thiamine-
deficient medium (TD); dark grey bars: high thiamine concentrations (HT). * p<0.05 vs NG ctrl 
  
19 
 
 
Fig. 4 Sp1 expression in retinal cells under different experimental conditions. a) Sp1 mRNA and b) protein 
expression in HMEC; c) Sp1 mRNA and d) protein expression in HRP; e) Sp1 mRNA and f) protein expression 
in MIO-M1 cells. Mean of 5 experiments ± SD, plus representative images of one relevant WB experiment. 
White bars: physiological thiamine concentrations (ctrl); light grey bars: thiamine-deficient medium (TD); 
dark grey bars: high thiamine concentrations (HT). * p<0.05 vs NG ctrl 
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Fig. 5 Expression of thiamine transporters and Sp1 in co-cultured retinal cells. a) THTR1 mRNA and b) 
protein expression; c) THTR2 mRNA and d) protein expression; e) Sp1 mRNA and f) protein expression. 
Mean of 5 experiments ± SD, plus representative images of one relevant WB experiment. White bars: 
physiological glucose concentrations (NG); light grey bars: high glucose concentrations (HG); dark grey bars: 
intermittent glucose concentrations (intHG). N=5, * p<0.05 vs NG 
  
21 
 
 
 
Fig. 6 Intracellular thiamine uptake and transketolase (TK) activity in retinal cells. a) intracellular thiamine 
uptake in HMEC; b) TK activity in HMEC; c) intracellular thiamine uptake in HRP; d) TK activity in HRP; e) 
intracellular thiamine uptake in MIO-M1 cells; b) TK activity in MIO-M1 cells. White bars: physiological 
thiamine concentrations (ctrl); light grey bars: thiamine-deficient medium (TD); dark grey bars: high 
thiamine concentrations (HT). N=5, * p<0.05 vs NG ctrl, ° p<0.05 vs NG HT, $ p<0.05 vs HG ctrl and HG HT, # 
p<0.05 vs intHG ctrl and intHG HT, £ p<0.05 vs intHG ctrl 
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Fig. 7 Permeability to thiamine of HMEC/HRP co-cultures. White bars: physiological thiamine 
concentrations (ctrl); light grey bars: thiamine-deficient medium (TD); dark grey bars: high thiamine 
concentrations (HT). N=5, * p<0.05 vs NG ctrl, ° p<0.05 vs NG HT, $ p<0.05 vs HG ctrl and HG HT, # p<0.05 vs 
intHG HT 
 
 
 
 
Fig. 8 Metabolic effects of reduced thiamine availability in retinal cells. a) Number of cells; b) cell 
proliferation; c) apoptosis; d) migration. White bars: physiological glucose and thiamine concentrations (NG 
ctrl); light grey bars: Physiological glucose + thiamine deficiency (NG TD); medium grey bars: high glucose + 
thiamine deficiency; dark grey bars: intermittent high glucose + thiamine deficiency (intHG TD). Results in 
b-c-d were normalized to cell number. N=5, * p<0.05 vs NG ctrl, $ p<0.05 vs NG TD, # p<0.05 vs HG TD 
 
